GSK and CureVac Restructure Partnership, Focusing on MRNA Vaccine Development
GSK and CureVac Restructure Partnership, Focusing on MRNA Vaccine Development
GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA development activities.
GSK plc（NYSE: GSK）和 Curerac N.V.（NASDAQ: CVAC）今天宣布，他们已经重组现有合作关系，并签署了一项新的许可协议，允许双方公司优先进行投资，并专注于各自的mRNA开发活动。
Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases. Through this collaboration, GSK and CureVac currently have vaccine candidates for seasonal influenza and COVID-19 in Phase 2 and avian influenza in Phase 1 clinical development. All candidates are based on CureVac's proprietary second-generation mRNA backbone. Data generated to date for these candidate vaccines are promising and demonstrate their potential to be best-in-class new vaccines.
自2020年以来，GSK和CureVac一直在共同开发用于传染病的mRNA疫苗。通过这种合作方式，GSK和CureVac目前拥有季节性流感和COVID-19的疫苗候选者进入第二阶段临床试验以及禽流感进入第一阶段临床试验。所有的候选疫苗都是基于CureVac专有的第二代mRNA骨架制备而成的。至今为止，这些候选疫苗的数据都很有前途，展示了它们成为最佳新型疫苗的潜力。
Under the terms of the new agreement, GSK will assume full control of developing and manufacturing these candidate vaccines. GSK will have worldwide rights to commercialise the candidate vaccines. The agreement represents the latest step in GSK's ongoing investment in vaccine platform technologies, matching the best platform to each pathogen to develop best-in-class vaccines. mRNA is an adaptable vaccine technology with demonstrated application in emerging and constantly changing viral pathogens due to its ability to support rapid strain change. GSK continues to develop and optimize its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing.
根据新协议的条件，GSK将完全控制这些候选疫苗的开发和制造。GSK将在全球范围内享有这些候选疫苗的商业化权利。该协议是GSK在疫苗平台技术方面持续投资的最新一步，将最佳平台与每个病原体匹配以开发最佳的疫苗。mRNA是一种可适应性强的疫苗技术，由于其支持快速株系变化的能力，在新兴和不断变化的病毒病原体的应用得到证明。GSK继续通过投资和合作关系发展和优化其mRNA能力，包括在基于人工智能/机器学习的序列优化、纳米粒子设计和制造方面的投资。
CureVac will receive an upfront payment of €400 million and up to an additional €1.05 billion in development, regulatory and sales milestones and tiered royalties in the high single to low teens range. The new agreement replaces all previous financial considerations from the prior collaboration agreement between GSK and CureVac. CureVac further retains exclusive rights to the additional undisclosed and preclinically validated infectious disease targets from the prior collaboration together with the freedom to independently develop and partner mRNA vaccines in any other infectious disease or other indication. CureVac's ongoing patent litigation against Pfizer/BioNTech is unaffected by the new agreement.
CureVac将获得4亿欧元的预付款，以及高单位到低青少年的分层版税，在开发、监管和销售里程碑方面最高可获得10.5亿欧元的额外奖励。新协议将取代GSK和CureVac之间的先前合作协议中的所有金融条款。CureVac还将保留先前合作中未公开并且已经完成临床验证的传染病靶点的独家权利以及在任何其他传染病或其他适应症中独立开发和合作的mRNA疫苗的自由。CureVac对辉瑞和BioNTech的持续专利诉讼不受新协议的影响。